In 2019,Journal of Medicinal Chemistry included an article by Zhao, Chao; Huang, Dane; Li, Ruyue; Xu, Yida; Su, Shimin; Gu, Qiong; Xu, Jun. Recommanded Product: 2510-22-7. The article was titled 《Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach》. The information in the text is summarized as follows:
In this paper, we applied a chemotype-assembly approach for ligand-based drug discovery (LBDD) to discover novel anti-osteoporosis leads. With this new approach, we identified 12 chemotypes and derived 18 major chemotype assembly rules from 245 known anti-osteoporosis compounds Then, we selected 19 compounds from an inhouse compound library using chemotype-assembly approach for anti-osteoporosis assays, which resulted in 13 hits. Based on structural features in these 13 compounds, we synthesized 50 possible anti-osteoporosis compounds from the anti-osteoporosis chemotypes by means of click chem. techniques and discovered a compound (10a, IC50 = 2 nM) with nanomolar activity. Compound 10a was then proved to be an anti-osteoporosis lead since it can prevent bone loss in vivo. After reading the article, we found that the author used 4-Ethynylpyridine(cas: 2510-22-7Recommanded Product: 2510-22-7)
4-Ethynylpyridine(cas: 2510-22-7) belongs to pyridine. In industry and in the lab, pyridine is used as a reaction solvent, particularly when its basicity is useful, and as a starting material for synthesizing some herbicides, fungicides, and antiseptics.Recommanded Product: 2510-22-7